Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Catherine Daniel"'
Autor:
Leila Zemoura, Damien Treguer, Nicolas Girard, Marie Brevet, A. Chapelier, Didier Decaudin, Olivier Deas, Sophie Chateau-Joubert, Stefano Cairo, Rania El Botty, Sergio Roman-Roman, André Nicolas, Didier Meseure, Ivan Bièche, Sophie Vacher, Ludmilla de Plater, Elodie Montaudon, Elisabetta Marangoni, Catherine Daniel, Fariba Nemati, Adnan Naguez, Alain Livartowski
Publikováno v:
Oncotarget. 12:859-872
Significant rational is available for specific targeting of PI3K/AKT/mTOR pathway in the treatment of non-small cell lung cancer (NSCLC). However, almost all clinical trials that have evaluated Pi3K pathway-based monotherapies/combinations did not ob
Autor:
Celene Y. L. Yap, Peter Kelly, George Braitberg, Catherine Daniel, Marie Gerdtz, Andrew Innes, Jonathan C Knott
Publikováno v:
International Journal of Mental Health Nursing. 29:796-807
Amphetamine-type stimulant use, including methamphetamine, amphetamine, and 3,4-methylenedioxymethamphetamine, is associated with a range of behavioural symptoms. Screening for amphetamine-type stimulant use among people presenting to the emergency d
Autor:
Catherine Daniel, Meghana Parsi
Publikováno v:
Cureus
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare drug-induced hypersensitivity reaction that manifests with a variety of signs and symptoms. It is an important condition that must be recognized by all physicians because if untr
Autor:
Isabelle Ray-Coquard, Jean-Christophe Thery, Lisa Ludwig, Jean-François Morère, Frédéric Selle, Richard Dorent, François Goldwasser, Gilbert Deray, Christelle Jouannaud, Vincent Launay-Vacher, Jean-Baptiste Rey, Olivier Mir, Florian Scotté, Stéphane Oudard, Jean-Philippe Spano, Joseph Gligorov, Catherine Daniel, Philippe Beuzeboc
Publikováno v:
Journal of Onco-Nephrology. 1:213-219
Background The potential prognostic value of hypertension and proteinuria of anti- vascular endothelial growth factor (VEGF) drugs has not been assessed in routine clinical practice so far in metastatic renal cell carcinoma (mRCC). The objectives wer
Autor:
Stéphane Oudard, Catherine Daniel, Vincent Launay-Vacher, J. C. Thery, Jean-Baptiste Rey, Jean-Philippe Spano, Nicolas Janus, Frédéric Selle, Christelle Jouannaud, François Goldwasser, Jean-François Morère, Philippe Beuzeboc, Isabelle Ray-Coquard, Joseph Gligorov, Gilbert Deray, Richard Dorent, Lisa Ludwig, Florian Scotté, Olivier Mir
Publikováno v:
Bulletin du Cancer. 102:906-914
Resume Introduction Les valeurs pronostiques de l’hypertension et de la proteinurie des anti-VEGF (facteur de croissance endothelial vasculaire) n’ont pas encore ete evaluees dans la pratique clinique de routine dans le cancer du sein (CS). Les o
Autor:
Nicolas Janus, Joseph Gligorov, J.-B. Rey, Florian Scotté, Gilbert Deray, R Dorent, François Goldwasser, J-C Thery, J-P Spano, P. Beuzeboc, Catherine Daniel, J-F. Morere, Michel Azizi, Christelle Jouannaud, Olivier Mir, I.L. Ray-Coquard, Vincent Launay-Vacher, Stéphane Oudard
Publikováno v:
Cancer Research. 73:P3-15
Background: Anti-VEGF drugs (AVD) are widely used in cancer patients (pts). Hypertension (HTN) and proteinuria (Pu) are class-side-effects of AVD, related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovasc
Autor:
Jean-Gabriel Judde, Pierre Laurent-Puig, Catherine Daniel, Fariba Nemati, Marie-France Poupon, Gonzague de Pinieux, Rui Bras-Gonçalves, Patricia de Cremoux, Vincent Bordier, Jean-Jacques Fontaine, Alain Livartowski, Didier Decaudin, A. Chapelier
Publikováno v:
Anti-Cancer Drugs. 20:932-940
The success of treatment of advanced non-small-cell lung cancer (NSCLC) remains very poor. The aim of this study was, on a series of NSCLC xenografts, to compare the efficacy of standard cisplatin-based or docetaxel-based chemotherapy. Seven human xe
Autor:
Gilles Robinet, Catherine Daniel, Maurice Pérol, D. Paillotin, A. Vergnenegre, E. Bouchaert, Jacques Letreut, Jean-Pierre Kleisbauer, Pierre Fournel, Hervé Lena, Pierre-Marie Preux, H. Le Caer
Publikováno v:
Lung Cancer. 47:395-404
Summary Context: The most satisfactory treatment for patients with locally advanced non-small-cell lung cancer (NSCLC) is combination chemotherapy–radiotherapy (CT–RT). The optimal treatment modalities remain to be determined. Objective: We condu
Autor:
J. Viala, L. Robert, Philippe Barthélémy, A. Riviere, T. Le Chevalier, Pierre Ruffié, H. Doubre, Karim Fizazi, Catherine Daniel, A. Fandi
Publikováno v:
Journal of Clinical Oncology. 21:349-354
Purpose: The aim of this open-label phase II study was to evaluate the activity of raltitrexed (Tomudex; AstraZeneca, Cergy, France) and oxaliplatin combination therapy in patients with diffuse malignant pleural mesothelioma. Patients and Methods: Fi
Autor:
Jérôme Solassol, Florence de Fraipont, Michele Faller, Franck Morin, Pascal Foucher, Ludovic Lacroix, Marie-Pierre Buisine, Martine Antoine, Bruno Coudert, Marie Wislez, Audrey Mauguen, Elisabeth Quoix, Guillaume Danton, Christos Chouaid, Bruno Chetaille, Gérard Zalcman, Jean-Pierre Pignon, Thierry Urban, Stephane Michiels, Virginie Westeel, Hélène Blons, Virginie Poulot, Jacques Cadranel, Catherine Daniel, Elisabeth Longchampt
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 7(10)
BackgroundEpidermal growth factor and v-Ki-ras2 Kirsten ras sarcoma (KRAS) mutation status, although associated with EGFR- tyrosine kinase inhibitor (TKI) efficacy, has not been used in clinical practice until recently. The prospective Evaluation of